ODP323 Increased Serum High-Sensitivity C-Reactive Protein Levels in Adult Growth Hormone Deficient Patients with Non-Functioning Pituitary Tumors

The source lists no authors.

Journal of the Endocrine Society1 Nov 2022

PMCIDPMC9626921PepBankPUB-94075432

Read at source Source pageAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. 1 result from people.

01HumanObservational studyOther
Among patients with non-functioning pituitary tumors, 46 (34%) had severe GH deficiency by the GHRP‑2 test.
In plain wordsIn people with non-functioning pituitary tumors, 34% had severe growth hormone deficiency on a GHRP‑2 test.
Peptide
GHRP-2
Outcome
Not applicablePrevalence of severe GH deficiency by GHRP-2 test
Study
n = 134
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Severe GHD
34%
GHRP-2 test
Source sentences
Summary
Among 134 patients (94 NFPA and 40 Rathke's cysts), 46 (34%) presented severe GH deficiency, as diagnosed using GHRP-2 tests.
1 context sentence(design, population, supporting numbers)
Summary · context
We retrospectively reviewed charts of 134 patients with non-functioning pituitary adenoma and Rathke's cysts who underwent preoperative GH-releasing peptide-2 (GHRP-2) tests and investigated the association between serum hs-CRP levels and background characteristics.
Report a problemFND-9407543201

Studies that did not test the peptide alone3

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

02HumanNot a test of GHRP-2 aloneObservational studyOther
Serum hs-CRP was significantly higher in patients with severe GH deficiency, defined by the GHRP‑2 test, than in those without.
In plain wordsPeople with severe growth hormone deficiency had higher blood hs-CRP, a marker of inflammation, than those without it.
Peptide
GHRP-2
Outcome
IncreaseSerum hs-CRP in severe GHD versus no severe GHD
Study
n = 134
Comparator
Patients without severe GH deficiency
Outcome group
Inflammation markers · Immune and inflammation
Measurements
Median hs-CRP
723 ng/mL
severe GHD
Median hs-CRP
278 ng/mL
no severe GHD
Source sentences
Summary
Serum hs-CRP levels were significantly higher in the patients with severe GH deficiency than in those without severe GH deficiency (723 [299-1285] vs 278 [124-561] ng/mL, P < 0. 001).
1 context sentence(design, population, supporting numbers)
Summary · context
We retrospectively reviewed charts of 134 patients with non-functioning pituitary adenoma and Rathke's cysts who underwent preoperative GH-releasing peptide-2 (GHRP-2) tests and investigated the association between serum hs-CRP levels and background characteristics.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-9407543202
03HumanNot a test of GHRP-2 aloneObservational studyOther
Peak GH response to GHRP‑2 was inversely correlated with serum hs-CRP.
In plain wordsA lower growth hormone peak in a GHRP‑2 test was linked to higher hs-CRP, a marker of inflammation.
Peptide
GHRP-2
Outcome
DecreaseCorrelation of peak GH response to GHRP-2 with hs-CRP
Study
n = 134
Outcome group
Inflammation markers · Immune and inflammation
Measurements
Spearman correlation
−0.47
peak GH response to GHRP-2 and hs-CRP
Source sentences
Summary
peak GH response to GHRP-2 (r s = -0.47, P < 0.
1 context sentence(design, population, supporting numbers)
Summary · context
We retrospectively reviewed charts of 134 patients with non-functioning pituitary adenoma and Rathke's cysts who underwent preoperative GH-releasing peptide-2 (GHRP-2) tests and investigated the association between serum hs-CRP levels and background characteristics.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-9407543203
04HumanNot a test of GHRP-2 aloneObservational studyOther
In multiple regression, peak GH response to GHRP‑2 was a significant determinant of serum hs-CRP after adjustment for other factors.
In plain wordsAfter adjusting for other factors, a lower growth hormone peak in a GHRP‑2 test was still linked to higher hs-CRP.
Peptide
GHRP-2
Outcome
DecreasePeak GH response to GHRP-2 as determinant of hs-CRP in multiple regression
Study
n = 134
Outcome group
Inflammation markers · Immune and inflammation
Measurements
Regression coefficient
−0.34
peak GH response to GHRP-2 and hs-CRP
Source sentences
Summary
In the multiple regression analysis, peak GH response to GHRP-2 was a significant variable for determining serum hs-CRP levels (β = -0.340, P = 0.
1 context sentence(design, population, supporting numbers)
Summary · context
We retrospectively reviewed charts of 134 patients with non-functioning pituitary adenoma and Rathke's cysts who underwent preoperative GH-releasing peptide-2 (GHRP-2) tests and investigated the association between serum hs-CRP levels and background characteristics.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-9407543204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Abstract

PepBank is a research reference. Talk to a doctor before you use any peptide.